Chronic Hepatitis B, C Linked With Lymphoma in HIV Patients

Article

This Medical News Minute examines a recent report that found that chronic infection with hepatitis B or C virus was associated with an increased risk for lymphoma among HIV patients on antiretroviral therapy.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara examines a new study that found that chronic infection with hepatitis B or C virus was associated with an increased risk for non-Hodgkin lymphoma among HIV patients on antiretroviral therapy.

Among treatment-naive patients, the hazard ratio (HR) for non-Hodgkin lymphoma with hepatitis B was 1.33 (95% CI, 0.69–2.56) and with hepatitis C was 0.67 (95% CI, 0.40–1.12). Among treated patients, the HR with hepatitis B was 1.74 (95% CI, 1.08–2.82) and with hepatitis C was 1.73 (95% CI, 1.21–2.46).

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content